UMB Bank n.a. Sells 1,502 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

UMB Bank n.a. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 112,122 shares of the biopharmaceutical company’s stock after selling 1,502 shares during the quarter. UMB Bank n.a.’s holdings in Gilead Sciences were worth $10,357,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. M.E. Allison & CO. Inc. bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $336,000. Aaron Wealth Advisors LLC raised its position in shares of Gilead Sciences by 15.7% in the fourth quarter. Aaron Wealth Advisors LLC now owns 10,839 shares of the biopharmaceutical company’s stock valued at $1,001,000 after purchasing an additional 1,474 shares during the period. Wealth Alliance Advisory Group LLC bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $220,000. Moss Adams Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 21.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 3,114 shares of the biopharmaceutical company’s stock worth $288,000 after acquiring an additional 555 shares during the last quarter. Finally, Sandbox Financial Partners LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter worth $211,000. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Wolfe Research assumed coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They issued an “outperform” rating and a $110.00 price objective on the stock. Barclays lifted their price target on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 7th. Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Mizuho lifted their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Finally, Bank of America reiterated a “buy” rating and set a $109.00 price target on shares of Gilead Sciences in a research note on Tuesday, December 10th. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 25,590 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 456,234 shares of company stock worth $42,130,461. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Trading Up 0.2 %

NASDAQ:GILD opened at $91.84 on Monday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The business has a 50 day moving average price of $91.75 and a two-hundred day moving average price of $84.08. The company has a market cap of $114.46 billion, a P/E ratio of 1,020.44, a price-to-earnings-growth ratio of 1.27 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the prior year, the firm posted $2.29 EPS. The business’s revenue was up 7.0% on a year-over-year basis. As a group, analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.35%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.